FDA, EMA and many national drug agencies have issued national recommendations and guidelines for ongoing clinical trials. They are focusing on providing support for patients, sites and investigators during the COVID-19 pandemic. Many of these guidelines suggest avoiding sites visits whenever possible as well as advice for remote monitoring visits.
USA, FDA
Coronavirus (COVID-19) Update: FDA Issues Guidance for Conducting Clinical Trials
Europe, EMA
Coronavirus disease (COVID-19) updates and regulations
Belgium, Federal Agency for Medicines and Health Products
Directive on direct drug delivery to patients in clinical trials
Germany, Federal Institute for Drugs and Medical Devices
Approval procedure (COVID-19 clinical trials)
Ireland, Irish Medicines Board
Italy,National Institute of Health
Ethical Framework for Health Care Institutions Responding to Novel Coronavirus SARS-CoV-2 (COVID-19)
UK, Medicines and Healthcare Regulatory Agency (MHRA)
MHRA update on novel coronavirus (COVID-19)
Bulgaria, Bulgarian Drug Agency
Guidance for sponsors conducing clinical trials (related to COVID-19 pandemic)
Netherlands, Medicines Evaluation Board
EMA plan for emerging health threats
Czech Republic, State Institute For Drug Control
Slovakia, State Institute for Drug Control
Emergency Measures For Clinical Trials Due to Covid-19
Hungary, National Institute of Pharmacy
Information on the continuity of clinical trials under COVID-19 (coronavirus) – 16/03/2020
Romania, National Medicines Agency
In the attention of companies conducting clinical studies in Romania
Lithuania, State Medicines Control Agency
Concerning the assurance of conducting clinical trials during the COVID-19 pandemic
Estonia, State Agency of Medicines
Clinical Trial Guide for the COVID-19 pandemic
Global, Real-time Tracker